Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant

Pharmacological Reports : PR
Magdalena Sowa-KućmaMagdalena Koperny

Abstract

The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of vortioxetine. Vortioxetine is a novel antidepressant, approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Because vortioxetine exhibits both an antidepressant and anxiolytic effect, it may be effective in treating both depressive and anxiety disorders, such as generalized anxiety disorder (GAD). Based on its pharmacodynamics profile and preclinical studies, it is believe that the drug's clinical action is mediated mainly by selective blockade of serotonin reuptake (by inhibiting the serotonin transporter [SERT]) and direct modulation of 5-HT receptors activity (such as 5-HT3, 5-HT7, 5-HT1D and 5-HT1B). In patients with MDD the recommended doses range is 5-20mg/day. Vortioxetine was shown to be more effective than placebo both in MDD and GAD. In terms of side effects, nausea, vomiting, diarrhea, and dry mouth were most commonly observed in individuals receiving vortioxetine. In direct comparison to duloxetine, vortioxetine is found to have a smaller efficacy but had a lower risk of developing the common antidepressant-induced adverse effects.

References

Feb 1, 2003·Biological Psychiatry·Pierre Blier, Nick M Ward
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·Brenda Costall, Robert J Naylor
Jun 1, 2009·Future Medicinal Chemistry·Adrian Hall
Sep 8, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Henriette Kold UldamLars Dalgaard
Dec 16, 2011·The Journal of Pharmacology and Experimental Therapeutics·A MørkT Bryan Stensbøl
Apr 13, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mette G HvenegaardLars Dalgaard
May 23, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alan L PehrsonConnie Sanchez
Aug 21, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anthony J RothschildDavid V Sheehan
Oct 24, 2012·The International Journal of Neuropsychopharmacology·Cécile BétryNasser Haddjeri
Jan 16, 2013·Pharmacological Reviews·David H Overstreet, Gregers Wegener
Feb 6, 2013·Pharmacology, Biochemistry, and Behavior·Arne MørkConnie Sanchez
Aug 7, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Kristian Gaarn du JardinAlan L Pehrson
Nov 29, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jesper Bornø JensenAlan Lars Pehrson
Dec 7, 2013·Drugs·Andrew Gibb, Emma D Deeks
Feb 27, 2014·Neuropsychiatric Disease and Treatment·Cornelius L Katona, Cara P Katona
May 24, 2014·The International Journal of Neuropsychopharmacology·Ashley WallaceDavid A Morilak
Jul 13, 2014·Pharmacology & Therapeutics·Connie SanchezFrancesc Artigas
Aug 26, 2014·CNS Drugs·Karly P Garnock-Jones
Oct 16, 2014·Journal of Psychopharmacology·Roger M Lane
Dec 20, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Cécile BétryNasser Haddjeri
Oct 16, 2015·Journal of Psychopharmacology·Stephan KöhlerMazda Adli
Jan 24, 2016·BMC Medicine·Beatrice BortolatoAndré F Carvalho

❮ Previous
Next ❯

Citations

May 19, 2020·Journal of Clinical Pharmacy and Therapeutics·Firouzeh BorhannejadShahin Akhondzadeh
May 26, 2020·Journal of Psychopharmacology·Emanuele CassioliFrancesco Rotella
Oct 15, 2019·Expert Opinion on Investigational Drugs·Bella SchanzerSanjay J Mathew
Sep 6, 2019·Journal of Clinical Pharmacy and Therapeutics·Azadeh SeddighniaShahin Akhondzadeh
Nov 30, 2019·Frontiers in Psychiatry·Djamila BennabiVincent Van Waes
Mar 12, 2020·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Domenico De BerardisMassimo Di Giannantonio
Sep 29, 2017·Frontiers in Pharmacology·Alaeddine DjillaniMarc Borsotto
Aug 10, 2017·Current Psychiatry Reports·Adam WichniakWojciech Jernajczyk
Dec 17, 2020·Neuropsychiatric Disease and Treatment·Yuan Wang, Miao Peng
Mar 23, 2021·Pharmacology & Therapeutics·Katarzyna MlyniecGabriel Nowak
Mar 23, 2021·Annals of General Psychiatry·Reiji YoshimuraAtsuko Ikenouchi
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kinga Sałat, Anna Furgała-Wojas
May 7, 2021·International Medical Case Reports Journal·Reiji YoshimuraYuki Konishi
Aug 13, 2021·Genes, Brain, and Behavior·Amalie ClementAyodeji A Asuni
Aug 28, 2021·International Journal of Molecular Sciences·Grzegorz ŚlifirskiJadwiga Turło
Nov 26, 2021·Fundamental & Clinical Pharmacology·Marija TodorovićRadica Stepanović-Petrović

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.